サルベージ化学療法としてgemcitabine,etoposide,cisplatinの3者併用化学療法が奏効した転移性尿管癌の1例

概要

論文の詳細を見る
35歳男.前化学療法(ifosfamide,5-FU,etoposide,cisplatinの併用)に抵抗性を示し,標題の3者併用療法によって完全緩解した.副作用として好中球減少と血小板減少を認めたが容認できる範囲と考えられたA 35-year-old man who had undergone nephroureterectomy and a single cycle of adjuvant MVAC chemotherapy for the left ureteral cancer was referred our clinic for the treatment of paraaortic lymph node metastases. Following histologic confirmation of transitional cell carcinoma by computed tomography (CT) guided biopsy, we treated him with combination chemotherapy consisting of ifosfamide, 5-fluorouracil, etoposide and cisplatin. After 5 cycles of chemotherapy complete remission was obtained. Six months later, however, metastases recurred in the left supraclavicular and paraaortic lymph nodes. Thus, we treated him with a new combination chemotherapy comprising gemcitabine, etoposide and cisplatin which was approved as a phase I study by the institutional review board. Although he was the first patient enrolled in the study and received the minimum dose of gemcitabine (level 1), complete remission was again achieved. Adjuvant radiotherapy of 40 Gy was given to the metastatic sites. He has been well without evidence of disease for 12 months.